Congress Program

* Subject to Change

Thursday, 13 December


08:00-09:00


Registration


09:00-09:10


Welcome and Opening of the Congress
Prof. Nir Peled, 
Israel | Chairman

 09:10-09:40
Keynote Lecture: Recent Updates in the Algorithm of NSCLC

Overview of the updates in NSCLC therapy over the last 2 years
Silvia Novello, University of Turin, Italy

09:40-11:10


Session 1
Screening for Lung Cancer – If, How and When?

 09:40-10:00


Are we Facing a Revolution in Screening for Lung Cancer in Europe Now?   

Current Consensus and the NELSON Recent Summary + Impact on Europe
Robert Pirker, Medical University of Vienna, Austria

10:00-10:20


Is There a Recommend Methodology in Screening Programs?

Mainly 2D vs. 3D technology of CT & measurement, time gaps between rounds of screening
Matthijs Oudkerk, University of Groningen, The Netherlands

10:20-10:40


Biomarkers to Serve Decisions in Screening Program

Review of biomarkers pre or post PSN finding
Gabriella Sozzi, Fondazione IRCCS Istituto Nazionale Tumori, Italy

 10:40-11:00  
SBRT for Early Disease
SBRT - overview, success, advantage & limitations
Aaron Allen, Davidoff Center, Israel


11:00-11:30


Networking, Coffee Break, Poster Viewing and Visit the Exhibition 

11:30-13:10


Session 2
Controversies in Pathology - Tissue Exhaustion, NGS and Liquid Alternative

 11:30-11:50


Challenges in the Pathology Lab

Advise tissue management and the required histology report
Phillipe Taniere, University Hospitals Birmingham NHS Foundation Trust, UK

11:50-12:10


Molecular Profiling in Lung Cancer - Upfront or Reflex Multiplex Approach?

Score of technologies considerations
Patrick Pauwels, University Hospital Antwerp, Belgium

 12:10-12:30


Liquid Biopsy - on Top or Replace the Pathology Lab?

Review of available methods, time to test (upfront/on progression) advantages
Christian Rolfo, University of Maryland School of Medicine, USA

 12:30-12:50

 

Bio-Informatics - Outsource or in-house Analysis?

Tools for bio-informatics and data management, pro-cons for outsource or in-house
Laila C. Roisman, Soroka Medical Center, Israel

 

 12:50-13:10
Annotating the NGS Report - Who's responsibility?
Present examples of NGS reports and tips for annotation. Who's responsible - the pathologist or the oncologist?
Miguel Ángel Molina, Pangaea Oncology, Spain


13:10-14:10


Lunch Break, Poster Viewing and Visit the Exhibition

14:10-15:10


Session 3
Debates in Thoracic Intervention

 14:10-14:30


Mini-Procedural Approaches in Thoracic Surgery

Review of procedures including LN sampling data
Pierluigi Novellis, Cancer Center Humanitas, Italy

 14:30-14:50


Stage IA (T1aN0M0) Lobectomy vs. Segmentectomy
Pro-cons each approach


14:50-15:10


Do we still Perform Pneumonectomy?

Review of indication, mortality, risks and outcome
Milton Saute, Rabin Medical Center - Campus Beilinson, Israel


15:10-15:40


Networking, Coffee Break, Poster Viewing and Visit the Exhibition 

15:40-16:10


Session 4
Debates in Stage III Disease
 

 15:40-15:55


Dosing for Chemo-RT and the "no fly zone"
Review of the dose for Chemo-RT and discuss centralize SBRT as an option
Raphael Pfeffer, Assuta Medical Center, Israel

 

 15:55-16:10
Consolidation Therapy Post Chemo-RT. A New Era?
Review of adjuvant therapies particularly for IO (Durvalumab)

      
16:10


End of Day One


Friday, 14 December



08:30-09:00


Registration

09:00-11:00


Session 5
Controversies in Advanced NSCLC

09:00-09:20


EGFR Therapy: How should we Start?
Discuss recent data of Osimertinib and its role in 1st or 2nd line + resistant pathways
Pascale Tomasini, Marseille Immunology Center, France

09:20-09:40


ALK Disease: Best First or Later and Do we Care about Variants?
Discuss recent data and sequence of therapy pro-cons with/out brain mets
Petros Christopoulos, University of Heidelberg, Germany

09:40-10:00
Brain Metastasis in NSCLC: Can we Hold the Trigger?
Review of brain activity for systemic disease

10:00-10:20
Do we have a Maximum Lesions for Brain SRS?
Review of the literature and technologies to allow avoidance from WBRT
Deborah BlumenthalTel Aviv Sourasky Medical Center, Israel

 10:20-10:40
What is Oligo Metastatic Disease in Lung Cancer?
Anne-Marie C. Dingemans, Maastricht University Medical Center, Netherlands
  


10:40-11:10


Networking, Coffee Break, Poster Viewing and Visit the Exhibition 

11:10-12:50


Session 6
Debates in Immunotherapy

 11:10-11:30


Recent Updates in Immunotherapy in Lung Cancer (NSCLC & SCLC)
Review of the last two years update in IO (NSCLC and SCLC)

11:30-11:50


PDL1>50% - Should we go Single or Combo?
Discuss clinical considerations for protocol selection among TMB, tumor burden, disease dissemination etc

11:50-12:10


What are the Best Biomarkers for IO in Lung Cancer?
Review updates and score predictive biomarkers for IO including PDL1, PDL2, TMB, KRAS, STK11 and others
Miguel Ángel Molina, Pangaea Oncology, Spain

 12:10-12:30


Re-Challenge of IO upon Toxicity or Progression. When, Why and Why not?
Discuss the considerations and the evidence for renewing IO therapy after toxicity or after remission and progression
Wilfried Eberhardt, University of Duisburg-Essen, Germany

 12:30-12:50
Disease Progression on IO. What are the Options?
Mechanism and clinical scenarios for disease progression under IO. Should we stop IO or rather add chemo or other maneuvers to control the disease
Rudolf M. HuberUniversity of Munich, Germany

 12:50-13:00  Discussion


13:00-14:00


Lunch Break, Poster Viewing and Visit the Exhibition

14:00-15:00


Session 7
Debates in Small Cell Lung Cancer

14:00-14:20


Treatment Algorithm in SCLC
Review the recent updates in the therapy for SCLC, including IO, RovaT and others

 14:20-14:40


PCI or MRI Monitoring in Limited SCLC
Challenge the PCI recommendation in SCLC
Paul Van Houtte,
Institute Jules Bordet, Belgium

 14:40-15:00  TBA


15:00-15:30


Networking, Coffee Break, Poster Viewing and Visit the Exhibition 

15:30-16:15


Session 8
Oral Presentations of Selected Abstracts

 15:30-15:45
Inter-Tumor Heterogeneity of PD-L1 Expression in Non-Small Cell Lung Cancer
Yuichi Saito, Sho Horiuchi, Hiroaki Morooka, Takayuki Ibi, Nobumasa Takahashi, Tomohiko Ikeya, Eishin Hoshi, Yoshihiko Shimizu, Saitama Cardiovascular and Respiratory Center, Japan

 15:45-16:00
Assist Oncologists to Upkeep Ethics & Confront Ethics Dilemmas using Evidences Based Lung Cancer Personalized Treatment Regimens Decisions Generated by Artificial Intelligence Software
Deva Datta Reddy Jyothi, Curative Technologies, India

 16:00-16:15
Circulating Tumor DNA Signature to Predict Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
Roxana Grinberg, Laila Roisman, Smadar Geva, Martina Lefterova, Katie Quinn, Lior Soussan Gutman, Addie Dvir, Roi Yair, Tal Twito, Richard Lanman, Nir Peled, Soroka University Medical Center, Israel

 16:15

Congress Closing